Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for Pliant Therapeutics (PLRX) over the last 6 years, with Q3 2025 value amounting to -$0.43.

  • Pliant Therapeutics' EPS (Basic) rose 5473.68% to -$0.43 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.87, marking a year-over-year increase of 1407.19%. This contributed to the annual value of -$3.47 for FY2024, which is 2632.29% down from last year.
  • According to the latest figures from Q3 2025, Pliant Therapeutics' EPS (Basic) is -$0.43, which was up 5473.68% from -$0.71 recorded in Q2 2025.
  • In the past 5 years, Pliant Therapeutics' EPS (Basic) registered a high of -$0.43 during Q3 2025, and its lowest value of -$0.95 during Q3 2024.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.71 (2025), whereas its average is -$0.74.
  • Per our database at Business Quant, Pliant Therapeutics' EPS (Basic) tumbled by 5957.45% in 2021 and then skyrocketed by 5473.68% in 2025.
  • Quarter analysis of 5 years shows Pliant Therapeutics' EPS (Basic) stood at -$0.68 in 2021, then dropped by 5.88% to -$0.72 in 2022, then grew by 4.17% to -$0.69 in 2023, then decreased by 19.06% to -$0.82 in 2024, then skyrocketed by 47.66% to -$0.43 in 2025.
  • Its EPS (Basic) was -$0.43 in Q3 2025, compared to -$0.71 in Q2 2025 and -$0.92 in Q1 2025.